Join
|
Contact
Join
|
Contact












News

Biomarker Resource Update: U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

Blurb: 
AbbVie (NYSE: ABBV) announced on May 14, 2025 that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.
Publication Date: 
Monday, July 14, 2025 - 3:00pm

Pages